Steve Krognes has served as a member of Guardant Health's Board since June 2022 and chairs the Audit Committee. He is a professional independent board member in the biotech and life sciences sector.
Before joining the Board, Mr. Krognes was the Chief Financial Officer at Denali Therapeutics Inc., a public biotechnology company, from October 2015 to April 2022. He joined Denali from Genentech, Inc., where he served as Chief Financial Officer and a member of the Executive Committee from April 2009 to September 2015. He also oversaw Genentech's Site Services organization between 2011 and 2015 and its IT organization between 2009 and 2011, and chaired the Genentech Access to Care Foundation between 2009 and 2015. From January 2004 to April 2009, Mr. Krognes served as Head of Mergers & Acquisitions and a member of the Finance Executive Committee at Roche Holding AG, and from July 2002 to December 2003 he served as Director of M&A at Danske Bank based in Norway.
Mr. Krognes currently serves on the boards of Denali Therapeutics Inc., argenx SE and Pliant Therapeutics, Inc., and previously served on the boards of Corvus Pharmaceuticals, Inc. (January 2016 to March 2021), RLS Global AB (January 2016 to January 2023) and Gritstone bio, Inc. (July 2018 to June 2024). He received his M.B.A. from Harvard Business School and his B.S. in Economics from The Wharton School of the University of Pennsylvania.